Stock · ARGX.BR · Healthcare
Netherlands · Large Cap · listed since 2017 · Revenue 2025 $4.2B
Price as of 11/06/2026
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Original text from the data provider
Summary
50.6 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €751.6M (2025), it supports €8.4B. The remaining €43.3B of the market value assume it grows 25.4% a year for 10 years and not at all afterwards.
Required FCF growth per year
25.4%
no growth afterwards
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q4 2024 → Q3 2026
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 17.64% | 11.52% | Rank 73 |
| Return on capital (Greenblatt) | 18.74% | 32.55% | Rank 24 |
| EBIT margin | 25.39% | 18.31% | Rank 72 |
| FCF margin | 20.33% | 14.12% | Rank 71 |
| Gross margin | 89.15% | 60.99% | Rank 97 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 89.64% | 8.04% | Rank 97 |
| Earnings growth, 3 years per yeardoes not count towards the rank | – | 5.44% | |
| Earnings growth, 5 years per yeardoes not count towards the rank | – | 7.00% | |
| Sustainable growth (ROE × retained earnings) | 0.15% | 3.66% | Rank 3 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 2.14% | 2.90% | Rank 31 |
| FCF yield | 1.45% | 3.63% | Rank 16 |
| EV/saleslower is better | 12.93 | 4.03 | Rank 10 |
| EV/EBITlower is better | 50.92 | 21.73 | Rank 7 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 1.03% | 8.66% | Rank 42 |
| Share price, 6 months | 22.10% | 24.27% | Rank 46 |
| Share price, 3 months | 12.02% | 15.42% | Rank 41 |
| Distance from 52-week high | −10.59% | −7.35% | Rank 38 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −5.14% | 0.30% | Rank 86 |
| Change in share countlower is better | 1.31% | 0.00% | Rank 11 |
| Dividend streak in yearsdoes not count towards the rank | – | 10 | |
| Price reaction to results, market-adjusted | 0.71% | 0.05% | Rank 57 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 84.34% | 48.40% | Rank 96 |
| Net debt/EBITDAlower is better | −3.32 | 1.11 | Rank 95 |
| Debt to equitylower is better | 0.01 | 0.48 | Rank 94 |
| Volatility, 1 yearlower is better | 39.70% | 31.42% | Rank 24 |
Ten years in figures
| Year | Revenue | EBIT margin | FCF, $M | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | $15.5M | −145.6% | 10.2 | 18.8M | −$94.5M |
| 2017 | $43.7M | −63.0% | −44.3 | 24.6M | −$229.0M |
| 2018 | $24.6M | −381.0% | −62.4 | 36.0M | −$321.5M |
| 2019 | $78.5M | −253.5% | 104.9 | 38.6M | −$364.8M |
| 2020 | $41.2M | −1,158.1% | −403.6 | 45.4M | −$1.2B |
| 2021 | $1.1B | −32.4% | −728.2 | 51.1M | −$1.3B |
| 2022 | $410.7M | −175.4% | −966.6 | 54.4M | −$788.3M |
| 2023 | $1.2B | −34.7% | −464.1 | 57.2M | −$2.0B |
| 2024 | $2.2B | −1.0% | −151.0 | 65.2M | −$1.5B |
| 2025 | $4.2B | 25.4% | 844.3 | 66.0M | −$3.4B |
3 of 7 StockScorer Score rules met · How the score is built
Argen-X mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Argen-X is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Argen-X.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 46.8 | 30.0 |
| P/B ratio | 8.3 | 4.8 |
| Return on equity (ROE) | 17.6% | 11.5% |
| Equity ratio | 84.3% | 48.4% |
| Debt-to-equity (D/E) | 0.01 | 0.48 |
| Dividend yield | – | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| ARGX.BR | Argen-Xthis page | |
| ARGX | argenx NV ADR | locked |
| 688235.SS | BeiGene Ltd. | locked |
| UCB.BR | UCB SA | locked |
| 207940.KS | Samsung Biologics Co Ltd | locked |
| CSL.AX | CSL Ltd | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.